Abstract
Central nervous system infections involving vancomycin-resistant Enterococcus faecium (VREF) are infrequently described and pose significant therapeutic difficulties, because these organisms are intrinsically resistant to many antibiotics. We describe the use of intrathecal quinupristin/dalfopristin to treat a VREF-associated infection in a neuro--surgical patient.
MeSH terms
-
Acetamides / therapeutic use
-
Anti-Bacterial Agents / administration & dosage
-
Anti-Bacterial Agents / pharmacology
-
Anti-Bacterial Agents / therapeutic use*
-
Drug Resistance, Microbial
-
Drug Resistance, Multiple*
-
Drug Therapy, Combination
-
Enterococcus faecium / drug effects
-
Enterococcus faecium / pathogenicity*
-
Fatal Outcome
-
Female
-
Gram-Positive Bacterial Infections / drug therapy*
-
Humans
-
Hydrocephalus / therapy
-
Injections, Intravenous
-
Injections, Intraventricular
-
Injections, Spinal
-
Linezolid
-
Middle Aged
-
Oxazoles / therapeutic use
-
Oxazolidinones*
-
Subarachnoid Hemorrhage / therapy
-
Tomography, X-Ray Computed
-
Vancomycin / pharmacology
-
Vancomycin / therapeutic use
-
Ventriculoperitoneal Shunt / adverse effects
-
Virginiamycin / administration & dosage
-
Virginiamycin / analogs & derivatives*
-
Virginiamycin / therapeutic use
Substances
-
Acetamides
-
Anti-Bacterial Agents
-
Oxazoles
-
Oxazolidinones
-
Virginiamycin
-
quinupristin
-
Vancomycin
-
Linezolid
-
dalfopristin